Related Experiment Video
Updated: May 11, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib
Jack Fitzsimons1, Kathleen Phelan2, Asha Dhanarajan3
1Department of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Introduction:
We present a case report of hearing loss in a patient with Waldenstrom macroglobulinemia (WM) receiving treatment with bortezomib.
Case Presentation:
Our patient developed sudden bilateral sensorineural hearing loss after receiving three doses of bortezomib. His hearing loss was irreversible and resulted in a cochlear implant.
Conclusion:
Hearing loss secondary to bortezomib is a known, but very rare, side effect. Hearing loss secondary to WM is also rare and has been described in case reports.

